Seno’s Imagio® breast imaging system can help providers distinguish, in real-time, between benign and malignant breast lesions.
It could soon be easier for radiologists to make an in-the-moment decision about whether a breast lesion is malignant or benign.
On Jan. 19, the U.S. Food & Drug Administration (FDA) granted pre-market approval (PMA) to the Imagio® Breast Imaging System from Seno Medical Instruments, Inc. This system uses non-invasive opto-acoustic ultrasound (OA/US) to help providers determine in real-time if an identified mass will require more invasive diagnostic evaluation.
Courtesy: Seno Medical Instruments, Inc.
Currently, breast biopsies due to false positives account for more than $2 billion in healthcare costs each year. Imagio®, which comes paired with an artificial intelligence decision support tool (SenoGram®) that helps providers transition from ultrasound to OA/US, could help this number drop, company officials said, by giving radiologists the information they need to be more confident in their assessments of lesions.
“Optimizing the diagnosis of breast masses requires a combination of very high sensitivity (more than 98 percent) while simultaneously maximizing specificity and minimizing false positives and biopsies of benign masses,” said Seno’s chief medical officer A. Thomas Starvos, M.D., FACR, FSBI. “Other modalities have reported improvements in specificity, but these have often come at the expense of the desired high more than 98 percent sensitivity.”
Results from the PMA study, he said, reveal that OA/US does reach improved specificity at fixed 98-percent sensitivity -- the area of the ROC curve where radiologists decide whether to biopsy.
To attain this level of performance, OA/US brings together laser optics and grayscale ultrasound for fused functional and anatomical breast imaging. Alongside anatomical images, according to company details, the technology provides a blood map of the breast masses and the surrounding area that can reveal the presence or absence of angiogenesis and deoxygenation – two cancer hallmarks. With this data, a radiologist can better make decisions about whether to expose a patient to more diagnostic imaging.
This system is intended for use by trained radiologists to identify palpable and non-palpable breast abnormalities in adults who have been referred for diagnostic imaging breast follow-up after a screening mammogram.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
GE HealthCare Launches AI Mammography Platform with Key Applications from iCAD
November 30th 2023Offering an all-in-one platform of artificial intelligence (AI) applications, MyBreastAI Suite reportedly facilitates early breast cancer detection and enhances efficiency with breast imaging workflows.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
Samsung Debuts New Ultrasound Modality Geared Toward Women's Health and Urology
November 15th 2023Combining enhanced imaging capabilities, workflow efficiencies and artificial intelligence (AI)-enabled technology to improve the diagnosis and management of health conditions in women, Samsung has launched the V6 ultrasound system.
Study Says Contrast-Enhanced Mammography Offers Comparable Breast Cancer Detection to MRI
November 15th 2023In findings from an enriched cohort of asymptomatic patients with screening-detected abnormalities, researchers found that contrast-enhanced mammography (CEM) was superior to conventional mammography and offered equivalent detection of breast cancer in comparison to breast MRI and abbreviated breast MRI.